Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Index by author

February 01, 1995; Volume 23,Issue 2
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Abadìa, A R

    1. You have access
      Disposition of ciprofloxacin in the isolated perfused rat liver.
      A R Abadìa, L De Francesco and A Guaitani
      Drug Metabolism and Disposition February 1995, 23 (2) 197-200;
  2. Andrews, P A

    1. You have access
      Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II).
      M Jennerwein and P A Andrews
      Drug Metabolism and Disposition February 1995, 23 (2) 178-184;
  3. Arison, B H

    1. You have access
      Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;

B

  1. Balani, S K

    1. You have access
      Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;
    2. You have access
      Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;
  2. Benoit, E

    1. You have access
      Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;
  3. Burka, L T

    1. You have access
      Metabolism and elimination of oxazepam in F344 rats.
      R J Griffin and L T Burka
      Drug Metabolism and Disposition February 1995, 23 (2) 232-239;
  4. Buronfosse, T

    1. You have access
      Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;

C

  1. Chakravarty, P K

    1. You have access
      Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
      R A Stearns, P K Chakravarty, R Chen and S H Chiu
      Drug Metabolism and Disposition February 1995, 23 (2) 207-215;
  2. Chen, I W

    1. You have access
      Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;
  3. Chen, R

    1. You have access
      Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
      R A Stearns, P K Chakravarty, R Chen and S H Chiu
      Drug Metabolism and Disposition February 1995, 23 (2) 207-215;
  4. Chenery, R J

    1. You have access
      Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
      S E Clarke, A W Harrell and R J Chenery
      Drug Metabolism and Disposition February 1995, 23 (2) 251-254;
  5. Cheraghali, A M

    1. You have access
      Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
      A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
      Drug Metabolism and Disposition February 1995, 23 (2) 223-226;
  6. Ching, M S

    1. You have access
      Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;
  7. Chiu, S H

    1. You have access
      Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
      R A Stearns, P K Chakravarty, R Chen and S H Chiu
      Drug Metabolism and Disposition February 1995, 23 (2) 207-215;
  8. Cho, A K

    1. You have access
      Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;
  9. Chu, T Y

    1. You have access
      Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;
  10. Clarke, S E

    1. You have access
      Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
      S E Clarke, A W Harrell and R J Chenery
      Drug Metabolism and Disposition February 1995, 23 (2) 251-254;

D

  1. De Francesco, L

    1. You have access
      Disposition of ciprofloxacin in the isolated perfused rat liver.
      A R Abadìa, L De Francesco and A Guaitani
      Drug Metabolism and Disposition February 1995, 23 (2) 197-200;
  2. Delatour, P

    1. You have access
      Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;
  3. Distefano, E W

    1. You have access
      Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;
  4. Divakaruni, P

    1. You have access
      Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.
      J A Ware, P Divakaruni and C K Svensson
      Drug Metabolism and Disposition February 1995, 23 (2) 295-297;
  5. Du Souich, P

    1. You have access
      Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits.
      P Du Souich, H Maurice and L Héroux
      Drug Metabolism and Disposition February 1995, 23 (2) 279-284;

E

  1. el Mansouri, S

    1. You have access
      Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

G

  1. Geerts, R J

    1. You have access
      Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;
  2. Ghabrial, H

    1. You have access
      Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;
  3. Griffin, R J

    1. You have access
      Metabolism and elimination of oxazepam in F344 rats.
      R J Griffin and L T Burka
      Drug Metabolism and Disposition February 1995, 23 (2) 232-239;
  4. Guaitani, A

    1. You have access
      Disposition of ciprofloxacin in the isolated perfused rat liver.
      A R Abadìa, L De Francesco and A Guaitani
      Drug Metabolism and Disposition February 1995, 23 (2) 197-200;
  5. Guengerich, F P

    1. You have access
      Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;

H

  1. Harrell, A W

    1. You have access
      Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
      S E Clarke, A W Harrell and R J Chenery
      Drug Metabolism and Disposition February 1995, 23 (2) 251-254;
  2. Héroux, L

    1. You have access
      Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits.
      P Du Souich, H Maurice and L Héroux
      Drug Metabolism and Disposition February 1995, 23 (2) 279-284;
  3. Heykants, J J

    1. You have access
      Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;
  4. Hiratsuka, A

    1. You have access
      Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;

J

  1. Jamali, F

    1. You have access
      Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis.
      M Piquette-Miller and F Jamali
      Drug Metabolism and Disposition February 1995, 23 (2) 240-245;
  2. Jennerwein, M

    1. You have access
      Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II).
      M Jennerwein and P A Andrews
      Drug Metabolism and Disposition February 1995, 23 (2) 178-184;
  3. Jeong, H G

    1. You have access
      Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;

K

  1. Kauffman, L R

    1. You have access
      Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;
  2. Knaus, E E

    1. You have access
      Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
      A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
      Drug Metabolism and Disposition February 1995, 23 (2) 223-226;
  3. Kumar, R

    1. You have access
      Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
      A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
      Drug Metabolism and Disposition February 1995, 23 (2) 223-226;

L

  1. Laurenzana, E M

    1. You have access
      Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
      E M Laurenzana, S L Sorrels and S M Owens
      Drug Metabolism and Disposition February 1995, 23 (2) 271-278;
  2. Leclerq, M

    1. You have access
      Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;
  3. Lee, H

    1. You have access
      Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;
  4. Lee, H S

    1. You have access
      Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;
  5. Lin, J H

    1. You have access
      Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;
  6. Lin, L Y

    1. You have access
      Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;
  7. Liu, Z C

    1. You have access
      Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
      Z C Liu, R A McClelland and J P Uetrecht
      Drug Metabolism and Disposition February 1995, 23 (2) 246-250;
  8. Longin-Sauvageon, C

    1. You have access
      Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;

M

  1. Mathai, L

    1. You have access
      Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;
  2. Matsunaga, T

    1. You have access
      Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
      K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
      Drug Metabolism and Disposition February 1995, 23 (2) 261-265;
  3. Maurice, H

    1. You have access
      Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits.
      P Du Souich, H Maurice and L Héroux
      Drug Metabolism and Disposition February 1995, 23 (2) 279-284;
  4. McClelland, R A

    1. You have access
      Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
      Z C Liu, R A McClelland and J P Uetrecht
      Drug Metabolism and Disposition February 1995, 23 (2) 246-250;
  5. Meuldermans, W E

    1. You have access
      Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;
  6. Miller, R R

    1. You have access
      Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;
  7. Morgan, D J

    1. You have access
      Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;
  8. Moroni, P

    1. You have access
      Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes.
      P Moroni, T Buronfosse, C Longin-Sauvageon, P Delatour and E Benoit
      Drug Metabolism and Disposition February 1995, 23 (2) 160-165;
  9. Mugford, C A

    1. You have access
      Contribution of oxidation and deacetylation to the bioactivation of acetaminophen in vitro in liver and kidney from male and female Sprague-Dawley rats.
      C A Mugford and J B Tarloff
      Drug Metabolism and Disposition February 1995, 23 (2) 290-294;

O

  1. Owens, S M

    1. You have access
      Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
      E M Laurenzana, S L Sorrels and S M Owens
      Drug Metabolism and Disposition February 1995, 23 (2) 271-278;

P

  1. Pang, K S

    1. You have access
      Kinetics of sequential metabolism. Contribution of parallel, primary metabolic pathways to the formation of a common, secondary metabolite.
      K S Pang
      Drug Metabolism and Disposition February 1995, 23 (2) 166-177;
    2. You have access
      Benzoic acid glycine conjugation in the isolated perfused rat kidney.
      K Poon and K S Pang
      Drug Metabolism and Disposition February 1995, 23 (2) 255-260;
  2. Perret, G

    1. You have access
      Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;
  3. Petitjean, O

    1. You have access
      Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;
  4. Piquette-Miller, M

    1. You have access
      Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis.
      M Piquette-Miller and F Jamali
      Drug Metabolism and Disposition February 1995, 23 (2) 240-245;
  5. Pitzenberger, S M

    1. You have access
      Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;
  6. Poon, K

    1. You have access
      Benzoic acid glycine conjugation in the isolated perfused rat kidney.
      K Poon and K S Pang
      Drug Metabolism and Disposition February 1995, 23 (2) 255-260;
  7. Porthault, M

    1. You have access
      Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

R

  1. Ramjit, H G

    1. You have access
      Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;
  2. Rho, J K

    1. You have access
      Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;
  3. Ring, J A

    1. You have access
      Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;

S

  1. Schmitz, D A

    1. You have access
      Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat.
      A Hiratsuka, T Y Chu, E W Distefano, L Y Lin, D A Schmitz and A K Cho
      Drug Metabolism and Disposition February 1995, 23 (2) 201-206;
  2. Schwartz, M S

    1. You have access
      Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;
  3. Shulkes, A

    1. You have access
      Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;
  4. Smallwood, R A

    1. You have access
      Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
      J A Ring, H Ghabrial, M S Ching, A Shulkes, R A Smallwood and D J Morgan
      Drug Metabolism and Disposition February 1995, 23 (2) 190-196;
  5. Sorrels, S L

    1. You have access
      Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
      E M Laurenzana, S L Sorrels and S M Owens
      Drug Metabolism and Disposition February 1995, 23 (2) 271-278;
  6. Stearns, R A

    1. You have access
      Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
      R A Stearns, P K Chakravarty, R Chen and S H Chiu
      Drug Metabolism and Disposition February 1995, 23 (2) 207-215;
    2. You have access
      Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.
      S K Balani, B H Arison, L Mathai, L R Kauffman, R R Miller, R A Stearns, I W Chen and J H Lin
      Drug Metabolism and Disposition February 1995, 23 (2) 266-270;
  7. Svensson, C K

    1. You have access
      Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.
      J A Ware, P Divakaruni and C K Svensson
      Drug Metabolism and Disposition February 1995, 23 (2) 295-297;

T

  1. Tarloff, J B

    1. You have access
      Contribution of oxidation and deacetylation to the bioactivation of acetaminophen in vitro in liver and kidney from male and female Sprague-Dawley rats.
      C A Mugford and J B Tarloff
      Drug Metabolism and Disposition February 1995, 23 (2) 290-294;
  2. Thompson, W J

    1. You have access
      Metabolism of L-689,502 by rat liver slices to potent HIV-1 protease inhibitors.
      S K Balani, S M Pitzenberger, M S Schwartz, H G Ramjit and W J Thompson
      Drug Metabolism and Disposition February 1995, 23 (2) 185-189;
  3. Tod, M

    1. You have access
      Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).
      S el Mansouri, M Tod, M Leclerq, O Petitjean, G Perret and M Porthault
      Drug Metabolism and Disposition February 1995, 23 (2) 227-231;

U

  1. Uetrecht, J P

    1. You have access
      Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
      Z C Liu, R A McClelland and J P Uetrecht
      Drug Metabolism and Disposition February 1995, 23 (2) 246-250;

V

  1. Van Beijsterveldt, L E

    1. You have access
      Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;

W

  1. Ware, J A

    1. You have access
      Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains.
      J A Ware, P Divakaruni and C K Svensson
      Drug Metabolism and Disposition February 1995, 23 (2) 295-297;
  2. Watanabe, K

    1. You have access
      Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
      K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
      Drug Metabolism and Disposition February 1995, 23 (2) 261-265;
  3. Wiebe, L I

    1. You have access
      Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
      A M Cheraghali, R Kumar, E E Knaus and L I Wiebe
      Drug Metabolism and Disposition February 1995, 23 (2) 223-226;
  4. Woestenborghs, R J

    1. You have access
      Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;
  5. Wuyts, K

    1. You have access
      Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.
      L E Van Beijsterveldt, R J Geerts, K Wuyts, R J Woestenborghs, W E Meuldermans and J J Heykants
      Drug Metabolism and Disposition February 1995, 23 (2) 216-222;

Y

  1. Yamamoto, I

    1. You have access
      Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
      K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
      Drug Metabolism and Disposition February 1995, 23 (2) 261-265;
  2. Yashimura, H

    1. You have access
      Oxidation of tolualdehydes to toluic acids catalyzed by cytochrome P450-dependent aldehyde oxygenase in the mouse liver.
      K Watanabe, T Matsunaga, I Yamamoto and H Yashimura
      Drug Metabolism and Disposition February 1995, 23 (2) 261-265;
  3. Yeleswaram, K

    1. You have access
      Relevance of tissue distribution studies.
      K Yeleswaram
      Drug Metabolism and Disposition February 1995, 23 (2) 159;
  4. Yun, C H

    1. You have access
      Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
      C H Yun, H S Lee, H Lee, J K Rho, H G Jeong and F P Guengerich
      Drug Metabolism and Disposition February 1995, 23 (2) 285-289;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 23, Issue 2
1 Feb 1995
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics